Reverse Merges in Biotech Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Reverse Merges in Biotech

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext

To: keokalani'nui who wrote (2)	6/13/2007 8:26:31 AM
From: Glenn Petersen	of 5

By my calculation, and I could be wrong, there will be 16.5 million common shares and 3.25 million warrants outstanding. It looks like the old shareholders of BTHC retained 300,000 shares and the shareholders of Athersys received 3.2 million shares. sec.gov The $65 million bought 13 million shares and 3.25 million warrants. Equity Financing. Signed subscriptions shall have been received to purchase no fewer than 8,000,000 units (the "Units") with a purchase price of $5.00 per Unit, each Unit consisting of one share of Parent Common Stock and a five-year warrant to buy 0.25 shares of Parent Common Stock at an exercise price of $6.00 per share, in a private placement offering exempt from registration under the Securities Act pursuant to Regulation D promulgated thereunder and otherwise pursuant to the terms outlined in the Private Placement Memorandum dated April 19, 2007 ("Equity Financing"), which subscriptions shall represent gross proceeds of not less than $40,000,000, with such gross proceeds having been fully funded into an escrow account established for the Equity Financing. sec.gov

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext